TrialJournal for immunotherapy of cancer2022

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer.

Wei Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.